In addition, targeted inhibition of PLK4 has emerged as a promising therapeutic strategy in the fight against cancer, supported by recent preclinical studies investigating the synthetic‐lethal relationship between TRIM37 amplification and PLK4 inhibition (Meitinger et al. 2020; Therapeutics 2023; Yeow et al. 2020). The gene discussed is PLK4; the disease is cancer.